SCHEMBL29413615

SCHEMBL29413615

O=C(OCc1ccccc1)N1CC2(CC2=O)C1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.55
MEN1 O00255 1/20 0.55
NPSR1 Q6W5P4 1/20 0.55
SMN1; SMN2 Q16637 4/20 0.54
NPC1 O15118 4/20 0.54
RAB9A P51151 4/20 0.54
CYP2C19 P33261 1/20 0.51
MAPK1 P28482 2/20 0.48
GAA P10253 1/20 0.48
L3MBTL1 Q9Y468 2/20 0.46
HTR2C P28335 2/20 0.46
CTRB1 P17538 1/20 0.46
P2RX4 Q99571 2/20 0.46
ALDH1A1 P00352 3/20 0.45
P2RX1 P51575 1/20 0.44
P2RX3 P56373 1/20 0.44
PSEN1 P49768 1/20 0.44
PSEN2 P49810 1/20 0.44
APH1B Q8WW43 1/20 0.44
NCSTN Q92542 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22468557 0.84 MEN1 (0.51) KMT2AMEN1NPSR1SMN1; SMN2NPC1
SCHEMBL15636331 0.84 MEN1 (0.54) KMT2AMEN1NPSR1SMN1; SMN2NPC1
SCHEMBL30703146 0.83 SMN1; SMN2 (0.49) KMT2AMEN1NPSR1SMN1; SMN2NPC1
SCHEMBL30703145 0.82 MEN1 (0.49) KMT2AMEN1NPSR1SMN1; SMN2NPC1
SCHEMBL20399800 0.82 NPC1 (0.53) KMT2AMEN1NPSR1SMN1; SMN2NPC1
SCHEMBL8326473 0.80 MEN1 (0.57) KMT2AMEN1NPSR1SMN1; SMN2NPC1
SCHEMBL9217126 0.80 KMT2A (0.56) KMT2AMEN1NPSR1SMN1; SMN2NPC1
SCHEMBL2673587 0.80 KMT2A (0.56) KMT2AMEN1NPSR1SMN1; SMN2NPC1
SCHEMBL10197546 0.80 KMT2A (0.56) KMT2AMEN1NPSR1SMN1; SMN2NPC1
SCHEMBL25259870 0.79 MEN1 (0.55) KMT2AMEN1NPSR1SMN1; SMN2NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109053523-B Azetidines as MEK inhibitors for the treatment of proliferative diseases 埃克塞利希斯股份有限公司 2022-03-25 CN disclosed